Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
about
Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependencyTargeting SH2 domains in breast cancerMetabolic history impacts mammary tumor epithelial hierarchy and early drug response in mice.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapyResistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samplesIntegrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.BRCA1 Alternative splicing landscape in breast tissue samples.Gene signatures in breast cancer: current and future uses.Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα.PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.Practical implications of gene-expression-based assays for breast oncologists.Predicting drug responsiveness in human cancers using genetically engineered mice.Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype.A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trialIntegrating breast cancer genetics into clinical practice.Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?Neoadjuvant treatments for triple-negative breast cancer (TNBC).Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion.Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients
P2860
Q24315549-AC2921B4-EB27-4119-A166-A404F6DE7D39Q27014674-953DF62D-FA67-4423-9EB0-59CAD36416D1Q30390384-8B9CC7DE-2CB5-4DFA-90C3-598947B463A8Q33573055-E622D5BC-FBD3-4647-8402-C4CCA73600B2Q33659361-8D6DFAF4-E54E-499C-836B-ABB2EEE20E28Q33820233-EA1850BC-9A99-4507-BE3F-7F31EB157209Q33827057-B88A82A5-123F-4CDE-BE37-8A59F360BD0EQ33914753-9C5288C3-5EB9-4D89-90D1-F8F262F07004Q34055901-051E640E-DEDE-4DB0-AB6C-9A73E55E2441Q34584599-7C7E9186-AC51-4F5B-937D-F13B375B7E92Q35079683-11DAC015-02AB-4BE4-9563-0ECCDD0933F8Q35368266-D8A499E7-B8EC-4975-8F53-43822AA73740Q36525765-234BB150-D323-439E-AD02-2B87C72E89EFQ36640582-04FA5DE1-4F61-4CA9-9364-E36D0F05552AQ36718459-5075A181-C806-435A-B46B-99C13D3C08F3Q36989546-16BDF089-09C7-4F1A-B031-A3A614362573Q37187379-DD7779D3-B5E5-4F2B-8011-64B57167DB0BQ37352137-B7B56E4C-CFBA-4606-A3AF-E21AEE10B5A1Q37580175-859044E1-870B-472E-8490-E48FFF3381E2Q37968654-A7D466DC-16A2-42A2-ABD8-595630940F4CQ37989074-64F08757-0689-4A57-9193-35AB7AB8349DQ38046580-5850F595-C2BB-4F84-8E66-DA929395E998Q38658509-947E11B9-E263-4B4C-9B60-908C1874D9E2Q39683758-79C72401-1C49-4C7A-8D5D-EFC0048197E7Q40039502-0A377C28-9FDC-4FAF-AE93-0C87A2A18116Q42442457-180FAF4C-9492-4515-9996-5ABF00359989Q42470916-45EB0CBF-BA06-4888-9353-997B9EBF1225Q43144068-DD6D5A3B-233A-4D57-B5DE-746EB4A95F71Q44358325-58832C10-1810-4E68-9650-41E060026100Q47121796-72B93F6D-5E6B-42BA-91E2-C327FC4EBC46Q52627272-C039B87D-0B9D-4628-9DDF-8C98CA7F025BQ53555841-D733BABE-A215-4CD6-B8EC-5BDB78A97F1BQ54942720-095459A8-75B1-4F13-BE32-DC44BFA5E6CDQ55066764-5E8C3ED9-3E99-4419-823D-27CAAE84F949Q57212856-2BF4DF14-E5E0-4D08-8CBE-B4AE106889E5
P2860
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
@en
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
@nl
type
label
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
@en
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
@nl
prefLabel
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
@en
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
@nl
P2093
P2860
P50
P1476
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
@en
P2093
J A García-Saenz
J A López García-Asenjo
J A Vidart
M C U Cheang
P2860
P2888
P304
P356
10.1007/S10549-011-1461-Y
P407
P577
2011-04-05T00:00:00Z
P5875
P6179
1043636339